A Randomised Controlled Trial Assessing the Efficacy of Balance Acceptance and Commitment Therapy (ACT) for Long COVID.

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This randomised controlled trial aims to investigate the efficacy of a psychological intervention for long COVID (LC) / post-COVID-19 syndrome (PCS) called Balance Acceptance and Commitment Therapy (Balance ACT). The primary objective of this trial is to investigate whether Balance-ACT improves quality of life over treatment as usual (i.e., self-help leaflet) in people with PCS/LC.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 or older

• LC/PCS diagnosis as defined by National Health Service (NHS) / National Institute for Health and Care Excellence (NICE) (i.e., symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis). A checklist will be used to ensure participants fulfil the diagnostic criteria as per the NICE guidelines

• Ability to travel to the research site for the study assessments

• Having registered with a General Practitioner (GP) in the United Kingdom (UK) and consent to provide their details for the study team to contact

• Ability to provide informed consent

• Ability to read and write English

Locations
Other Locations
United Kingdom
King's College London
RECRUITING
Camberwell
Contact Information
Primary
Trudie Chalder, PhD
trudie.chalder@kcl.ac.uk
+44 (0)20 7848 0406
Backup
Caroline Jolley, PhD
caroline.jolley@kcl.ac.uk
Time Frame
Start Date: 2024-06-04
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 196
Treatments
Experimental: Balance ACT
Participants randomised to Balance ACT will receive 10 therapy sessions with a therapist.
No_intervention: Treatment as usual
Information leaflet about PCS/LC.
Related Therapeutic Areas
Sponsors
Leads: King's College London

This content was sourced from clinicaltrials.gov